Kidney Failure

Nephrology
5
Pipeline Programs
5
Companies
5
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
2
1
0
0
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

5 companies ranked by most advanced pipeline stage

T-Therapeutics
T-TherapeuticsUK - Cambridge
1 program
1
glecaprevir/pibrentasvir tabletsPhase 41 trial
Active Trials
NCT03623568WithdrawnEst. Apr 2021
Veloxis Pharmaceuticals
1 program
1
TacrolimusPhase 21 trial
Active Trials
NCT00765661CompletedEst. Feb 2010
Ossium Health
Ossium HealthIN - Indianapolis
1 program
1
Bone Marrow TransplantPhase 1/21 trial
Active Trials
NCT05900401Active Not RecruitingEst. Dec 2030
Rockwell Medical
1 program
1
Soluble Ferric PyrophosphatePhase 1/21 trial
Active Trials
NCT01894906CompletedEst. Sep 2013
Eledon Pharmaceuticals
1 program
1
Combined Kidney/Bone Marrow TransplantPhase 11 trial
Active Trials
NCT06972069RecruitingEst. Dec 2030

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
T-Therapeuticsglecaprevir/pibrentasvir tablets
Veloxis PharmaceuticalsTacrolimus
Ossium HealthBone Marrow Transplant
Rockwell MedicalSoluble Ferric Pyrophosphate
Eledon PharmaceuticalsCombined Kidney/Bone Marrow Transplant

Clinical Trials (5)

NCT03623568T-Therapeuticsglecaprevir/pibrentasvir tablets

Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Kidney Transplant

Start: Feb 2019Est. completion: Apr 2021
Phase 4Withdrawn
NCT00765661Veloxis PharmaceuticalsTacrolimus

Pharmacokinetics of LCP-Tacro(TM) Once Daily And Prograf® Twice A Day in Adult De Novo Kidney Transplant Patients

Start: Sep 2008Est. completion: Feb 2010
Phase 2Completed
NCT05900401Ossium HealthBone Marrow Transplant

Delayed Tolerance Through Mixed Chimerism

Start: Oct 2023Est. completion: Dec 2030
Phase 1/2Active Not Recruiting
NCT01894906Rockwell MedicalSoluble Ferric Pyrophosphate

Quantitative Mass Transfer of SFP-iron From Dialysate to Blood in CKD-HD Patients

Start: Jul 2013Est. completion: Sep 2013
Phase 1/2Completed
NCT06972069Eledon PharmaceuticalsCombined Kidney/Bone Marrow Transplant

Tolerance Through Mixed Chimerism (Sip-Tego)

Start: May 2025Est. completion: Dec 2030
Phase 1Recruiting

Related Jobs in Nephrology

Thesis work, 60 credits – Establishing In Vitro Models of Mitochondrial Dysfunction in Acute Kidney Injury for Preclinical Drug Discovery

AstraZeneca
Sweden - Gothenburg
1w ago

Associate Director – Nephrology Market Access Strategy

Biogen
Cambridge, MA
1w ago
$164K - $226K/yr

Director, Strategy & Operations-Nephrology Franchise

Biogen
Cambridge, MA
1w ago
$195K - $269K/yr

Medical Science Liaison, CardioRenal - Portland, OR

AstraZeneca
Portland - OR, US
1w ago

Vice President, Head of Renal Sales

Novartis
Field Non-Sales (USA)
1w ago
$274K - $510K/yr

Specialty Account Manager, Nephrology- South Houston, Texas

Amgen
Texas - Houston, US
1w ago
$155K - $184K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials
5 companies competing in this space

Related Indications

Chronic Kidney Disease(86)Renal Impairment(67)End Stage Renal Disease(56)Kidney Transplantation(49)Renal Insufficiency(27)Chronic Kidney Diseases(25)Kidney Transplant(19)Diabetic Nephropathies(18)Kidney Diseases(17)Kidney Transplant Rejection(16)